Zealand Pharma, a biotechnology company pioneering the future of metabolic health, announced a strategic agreement with AI infrastructure firm DCAI to harness Gefion, Denmark’s state-of-the-art supercomputer, in its drug discovery efforts.

The partnership will allow Zealand Pharma to integrate enterprise-scale artificial intelligence into its research and development workflows, generating proprietary insights that aim to enhance both the quality and efficiency of medicine creation. This move supports the company’s ambitious Metabolic Frontier 2030 strategy.

Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs, providing scalable, flexible computational power for large-scale protein–peptide simulations. Combined with Zealand Pharma’s 25 years of peptide research expertise, the platform enables advanced characterization, simulation, and generative AI modeling for next-generation drug design.

"By integrating DCAI’s powerful AI infrastructure into our research workflows, Zealand Pharma is fundamentally transforming our approach to peptide discovery and design,” said Utpal Singh, Chief Scientific Officer of Zealand Pharma.

“Gefion’s computational power will generate new insights that augment the expertise of our scientists. These enhanced capabilities directly support our Metabolic Frontier 2030 strategy, including our ambition to deliver more than 10 clinical programs and achieve industry-leading cycle times from idea to clinic by 2030.

"Combined with our deep peptide expertise, this computationally driven approach positions Zealand Pharma to lead the next generation of metabolic health innovation while maintaining the rigorous scientific standards that define our leadership in peptide therapeutics.”

For DCAI, the collaboration represents a milestone in its mission to accelerate life sciences through AI.

“Working with Zealand Pharma marks a significant important milestone for DCAI as we continue to accelerate life sciences and biotechnology through impactful AI,” said Nadia Carlsten, CEO of DCAI.

“It’s rewarding to see innovative customers use our AI capabilities and translate them into measurable scientific and clinical outcomes: by providing scalable AI computing for Zealand Pharma’s peptide discovery initiatives, we can help reduce development timelines and contribute to innovative metabolic treatments for patients around the world.”